MTIM
LFCR icon

Marathon Trading Investment Management’s Lifecore Biomedical LFCR Stock Holding History

Marathon Trading Investment Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,900
Closed -$106K – 353
2024
Q1 		$106K Buy
+19,900
New +$142K 0.01% 295

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Marathon Trading Investment Management's LFCR Position: Q2 2024 in Review

Marathon Trading Investment Management sold out of Lifecore Biomedical (LFCR) in Q2 2024, closing a stake of 19,900 shares — an estimated $106K sold.

Marathon Trading Investment Management first reported a position in LFCR in Q1 2024 and held it in 1 quarter. The position peaked at $106K in Q1 2024. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2024.

  • Marathon Trading Investment Management reported no remaining Lifecore Biomedical position as of Q2 2024 after selling out during the quarter.
  • Marathon Trading Investment Management sold 19,900 Lifecore Biomedical shares in Q2 2024, an estimated $106K.
  • Marathon Trading Investment Management first reported a position in Lifecore Biomedical in Q1 2024 and held it in 1 quarter.
  • Marathon Trading Investment Management's Lifecore Biomedical position peaked at $106K in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2024.

Based on Marathon Trading Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.